阿尔茨海默病中增强和恢复溶酶体功能的途径研究进展

doi:10.3969/j.issn.1003-9198.2026.02.015

摘要/Abstract

摘要： 溶酶体功能障碍是AD病理机制的重要一环,其功能修复为疾病干预提供新契机。本文系统综述了溶酶体功能恢复的六大策略:转录因子EB的激活与调控、自噬-溶酶体途径的调节、中医药干预、运动疗法、纳米材料的应用及新型溶酶体增强剂的开发,重点探讨其分子机制、模型验证及临床转化潜力。通过整合基础研究与转化医学进展,本文旨在为AD治疗提供理论依据与创新方向。

关键词: 阿尔茨海默病, 溶酶体, 转录因子EB, 自噬, 中医药, 纳米技术

Abstract: Lysosomal dysfunction is an important part of the pathological mechanism of Alzheimer’s disease, and its functional repair provides a new opportunity for disease intervention. This paper systematically reviews six major strategies for restoring lysosomal function: activation and regulation of transcription factor EB, modulation of the autophagy-lysosome pathway, traditional Chinese medicine interventions, exercise therapy, application of nanomaterials, and the development of novel lysosomal enhancers. It also provides an in-depth discussion of the molecular mechanisms, model validation, and clinical translation potential. By integrating basic research and advances in translational medicine, this review aims to provide a theoretical basis and innovative direction for Alzheimer’s disease therapy.

Key words: Alzheimer’s disease, lysosome, transcription factor EB, autophagy, traditional Chinese medicine, nanotechnology

中图分类号:

R 749.16

杨馨, 石胜良. 阿尔茨海默病中增强和恢复溶酶体功能的途径研究进展[J]. 实用老年医学, 2026, 40(2): 180-184.

YANG Xin, SHI Shengliang. Research progress on the pathways of enhancing and restoring lysosomal function in Alzheimer’s disease[J]. Practical Geriatrics, 2026, 40(2): 180-184.

参考文献

[1] NIXON R A, RUBINSZTEIN D C. Mechanisms of autophagy-lysosome dysfunction in neurodegenerative diseases[J]. Nat Rev Mol Cell Biol, 2024, 25(11): 926-946.
[2] CHEN M, DAI Y, LIU S, et al. TFEB biology and agonists at a glance[J]. Cells, 2021, 10(2): 333.
[3] ABOKYI S, GHARTEY-KWANSAH G, TSE D Y. TFEB is a central regulator of the aging process and age-related diseases[J]. Ageing Res Rev, 2023, 89: 101985.
[4] NAH J, SUNG E A, ZHAI P, et al. Tfeb-mediated transcriptional regulation of autophagy induces autosis during ischemia/reperfusion in the heart[J]. Cells, 2022, 11(2): 258.
[5] TAKLA M, KESHRI S, RUBINSZTEIN D C. The post-translational regulation of transcription factor EB (TFEB) in health and disease[J]. EMBO Rep, 2023, 24(11): e57574.
[6] WANG B, MARTINI-STOICA H, QI C, et al. TFEB-vacuolar ATPase signaling regulates lysosomal function and microglial activation in tauopathy[J]. Nat Neurosci, 2024, 27(1): 48-62.
[7] ZHANG Y D, ZHAO J J. TFEB participates in the Aβ-induced pathogenesis of Alzheimer’s disease by regulating the autophagy-lysosome pathway[J]. DNA Cell Biol, 2015, 34(11): 661-668.
[8] XU Y, WANG Q, WANG J, et al. The cGAS-STING pathway activates transcription factor TFEB to stimulate lysosome biogenesis and pathogen clearance[J]. Immunity, 2025, 58(2): 309-325.e6.
[9] YANG C, SU C, IYASWAMY A, et al.Celastrol enhances transcription factor EB (TFEB)-mediated autophagy and mitigates Tau pathology: implications for Alzheimer’s disease therapy[J]. Acta Pharm Sin B, 2022, 12(4): 1707-1722.
[10] LI T, YIN L, KANG X, et al. TFEB acetylation promotes lysosome biogenesis and ameliorates Alzheimer’s disease-relevant phenotypes in mice[J]. J Biol Chem, 2022, 298(12): 102649.
[11] WANG Y, HUANG Y, LIU J, et al. Acetyltransferase GCN5 regulates autophagy and lysosome biogenesis by targeting TFEB[J]. EMBO Rep, 2020, 21(1): e48335.
[12] WANG X, XIE Y, CHEN G, et al. Intermittent hypoxia therapy ameliorates beta-amyloid pathology via TFEB-mediated autophagy in murine Alzheimer’s disease[J]. J Neuroinflammation, 2023, 20(1): 240.
[13] ZHANG Z, YANG X, SONG Y Q, et al.Autophagy in Alzheimer’s disease pathogenesis: therapeutic potential and future perspectives[J]. Ageing Res Rev, 2021, 72: 101464.
[14] WANG J, LIU B, XU Y, et al. Activation of CREB-mediate dautophagy by thioperamide ameliorates β-amyloid pathology and cognition in Alzheimer’s disease[J]. Aging Cell, 2021, 20(3): e13333.
[15] NIXON R A. Autophagy-lysosomal-associated neuronal death in neurodegenerative disease[J]. Acta Neuropathol, 2024, 148(1): 42.
[16] TONG B C, HUANG A S, WU A J, et al.Tetrandrine ameliorates cognitive deficits and mitigates tau aggregation in cell and animal models of tauopathies[J]. J Biomed Sci, 2022, 29(1): 85.
[17] KIM S, KIM D K, JEONG S, et al. The common cellular events in the neurodegenerative diseases and the associated role of endoplasmic reticulum stress[J]. Int J Mol Sci, 2022, 23(11): 5894.
[18] LI S, WU Z, LE W. Traditional Chinese medicine for dementia[J]. Alzheimers Dement, 2021, 17(6): 1066-1071.
[19] JIE K, CAIYI S, XIN L. Etiology and pathogenesis of Alzheimers disease based on the theory of traditional Chinese medicine[J]. J Biomed Res Environ Sci, 2022, 3(12): 1413-1417.
[20] LI S, YANG J. Pathogenesis of Alzheimer’s disease and therapeutic strategies involving traditional Chinese medicine[J]. RSC Med Chem, 2024, 15(12): 3950-3969.
[21] IYASWAMY A, KRISHNAMOORTHI S K, ZHANG H, et al.Qingyangshen mitigates amyloid-β and Tau aggregate defects involving PPARα-TFEB activation in transgenic mice of Alzheimer’s disease[J]. Phytomedicine, 2021, 91: 153648.
[22] YIN P, WANG H, XUE T, et al. Four-dimensional label-free quantitative proteomics of ginsenoside Rg₂ ameliorated scopolamine-induced memory impairment in mice through the lysosomal pathway[J]. J Agric Food Chem, 2024, 72(26): 14640-14652.
[23] ZENG P, SU H F, YE C Y, et al. A tau pathogenesis-based network pharmacology approach for exploring the protections of Chuanxiong rhizoma in Alzheimer’s disease[J]. Front Pharmacol, 2022, 13: 877806.
[24] ZHAO Y, LONG Z, DING Y, et al. Dihydroartemisinin ameliorates learning and memory in Alzheimer’s disease through promoting autophagosome-lysosome fusion and autolysosomal degradation for Aβ clearance[J]. Front Aging Neurosci, 2020, 12: 47.
[25] 栗晨璐, 杨晓坤, 高誉珊, 等.基于内体-溶酶体系统探讨电针“百会”“涌泉”改善APP/PS1双转基因小鼠学习记忆能力的作用机制[J].针刺研究, 2023, 48(8):791-798.
[26] CARDONA M I, AFI A, LAKICEVIC N, et al. Physical activity interventions and their effects on cognitive function in people with dementia: a systematic review and meta-analysis[J]. Int J Environ Res Public Health, 2021, 18(16): 8753.
[27] YUEDE C M, TIMSON B F, HETTINGER J C, et al. Interactions between stress and physical activity on Alzheimer’s disease pathology[J]. Neurobiol Stress, 2018, 8: 158-171.
[28] DE LA ROSA A, OLASO-GONZALEZ G, ARC-CHAGNAUD C, et al. Physical exercise in the prevention and treatment of Alzheimer’s disease[J]. J Sport Health Sci, 2020, 9(5): 394-404.
[29] HUANG X, ZHAO X, LI B, et al. Comparative efficacy of various exercise interventions on cognitive function in patients with mild cognitive impairment or dementia:a systematic review and network meta-analysis[J]. J Sport Health Sci, 2022, 11(2): 212-223.
[30] 贾俊, 周迎松, 楼琼, 等. 运动调控自噬溶酶体通路改善阿尔茨海默病的机制[J]. 生物化学与生物物理进展, 2023, 50(10): 2314-2324.
[31] JIAN Y, YUAN S, YANG J, et al. Aerobicexercise alleviates abnormal autophagy in brain cells of APP/PS1 mice by upregulating AdipoR1 levels[J]. Int J Mol Sci, 2022, 23(17): 9921.
[32] WU J J, YU H, BI S G, et al. Aerobic exercise attenuatesautophagy-lysosomal flux deficits by ADRB2/β2-adrenergic receptor-mediated V-ATPase assembly factor VMA21 signaling in APP-PSEN1/PS1 mice[J]. Autophagy, 2024, 20(5): 1015-1031.
[33] ZHAO N, ZHANG X, SONG C, et al. The effects of treadmill exercise on autophagy in hippocampus of APP/PS1 transgenic mice[J]. Neuroreport, 2018, 29(10): 819-825.
[34] WANG X, ZHU Y T, ZHU Y, et al. Long-term running exercise alleviates cognitive dysfunction in APP/PSEN1 transgenic mice via enhancing brain lysosomal function[J]. Acta Pharmacol Sin, 2022, 43(4): 850-861.
[35] YIN T, LIU Y, HE B, et al. Cell primitive-basedbiomimetic nanomaterials for Alzheimer’s disease targeting and therapy[J]. Mater Today Bio, 2023, 22: 100789.
[36] FAN Z, REN T, WANG Y, et al. Aβ-responsive metform in-based supramolecular synergistic nanodrugs for Alzheimer’s disease via enhancing microglial Aβ clearance[J]. Biomaterials, 2022, 283: 121452.
[37] RATHORE B, SUNWOO K, JANGILI P, et al.Nanomaterial designing strategies related to cell lysosome and their biomedical applications: a review[J]. Biomaterials, 2019, 211: 25-47.
[38] KANAZIRSKA M V, FUCHS P M, CHEN L, et al. Beneficial effects of lysosome-modulating and other pharmacological and nanocarrier agents on amyloid-beta-treated cells[J]. Curr Pharm Biotechnol, 2012, 13(15): 2761-2767.
[39] HAO M, CHU J, ZHANG T, et al.Nanomaterials-mediated lysosomal regulation: a robust protein-clearance approach for the treatment of Alzheimer’s disease[J]. Neural Regen Res, 2025, 20(2): 424-439.
[40] WU Q, KARTHIVASHAN G, NAKHAEI-NEJAD M, et al. Native PLGA nanoparticles regulate APP metabolism and protect neurons against β-amyloid toxicity: potential significance in Alzheimer’s disease pathology[J]. Int J Biol Macromol, 2022, 219: 1180-1196.
[41] FENG Y, FU H, ZHANG X, et al. Lysosome toxicities induced by nanoparticle exposure and related mechanisms[J]. Ecotoxicol Environ Saf, 2024, 286: 117215.
[42] VEST R T, CHOU C C, ZHANG H, et al. Small molecule C381 targets thelysosome to reduce inflammation and ameliorate disease in models of neurodegeneration[J]. Proc Natl Acad Sci USA, 2022, 119(11): e2121609119.
[43] ZHOU J, WANG N, WANG M, et al. Discovery and optimization of tetrahydroisoquinoline derivatives to enhance lysosome biogenesis as preclinical candidates for the treatment of Alzheimer’s disease[J]. J Med Chem, 2024, 67(11): 8836-8861.